Could you share some significant milestones from your career?
With over 25 years at the helm as Managing Director of Ami Polymer Pvt. Ltd. (APPL), me and my dynamic team have led the company to international prominence as a key player in providing silicone rubber solutions for the pharmaceutical, food, and engineering sectors. My academic foundation includes an MBA in Marketing from the prestigious Jamnalal Bajaj Institute of Management Studies and an Engineer’s Degree in Rubber Technology from L.D College of Engineering.
My overarching mission is centred around delivering Innovative, exceptional and trustworthy silicone products with my team that align with the diverse needs and rigorous standards of our global customer base and partners. Collaborating with a team of highly motivated rubber technologists, we have led the establishment of 2 advance manufacturing site, one is equipped with ISO clean room Class 10000 rating in Silvassa Masat, and another new facility at Kala with total 3,50,000 sq. feet of area, which has a ISO clean room of 1,00,000 sq. feet area from clean room class 5 to 8 and complemented by a robust head office in Mumbai.
This strategic approach has been instrumental in expanding our marketing footprint across 12 Indian regional offices, 1 International office in USA and establishing a distribution network spanning over 50+ countries, including key regions such as the USA, Europe, , UK, Asia & Middle east. I’ve diligently ensured that our products attain certifications from esteemed bodies such as TOXIKON, BPOG, USP Class VI, and NSF-51, underscoring our unwavering commitment to quality and safety.
Also I am proud to share that we have vaccinated the Indian population via validating our Imapure tubing inglobal vaccine manufactures.
Could you provide insights into the mission and vision of Ami Polymer and when it was founded?
Founded in 1998, Ami Polymer has been a pioneer in the Silicone Elastomeric products and a diverse range of Polymeric components, offering comprehensive solutions for Fluid Transfers, Sealing, and Contamination controls across global sectors such as Biopharma, Pharma, Medical, Laboratory, Food, Beverages, and Engineering.
Vision & Mission: “Partnering with Life-Sciences Community through Innovative Polymer Solutions for Affordable Healthcare.”
What are the core products in Ami Polymer’s portfolio?
Ami Polymer’s portfolio comprises essential products that cater to diverse industry needs. Our core offerings include Platinum cured silicone and thermoplastic tubing braided hoses, single-use 2D and 3D bags, assemblies, components, inflatable seals, Tri-clover gaskets, silicone medical implants, and custom-molded parts.
These products collectively embody our commitment to providing comprehensive solutions across various sectors.
To know more about our range of products & quality please visit our company site: www.amipolymer.com
Which sectors make up your target audience?
Our extensive array of products and versatile capabilities position us as a key supplier to a diverse range of industries. We serve the needs of the Pharma, Biopharma, Food & Beverages, Medical, veterinary and Engineering sectors with our high-quality solutions & certification such as: FDA 21 CFR, USP Class VI, EP 3.1.9, ADI Free, RoHS, NSF-51.
Could you elaborate on the technologies employed in your production processes?
APPL employs advanced manufacturing technologies, ensuring end-to-end process capabilities to meet the diverse needs of our customers. Our advanced facilities incorporate Extrusion Technology with a Laser Controlled system, Automatic Hose Production lines, Plastic Extrusion Lines, Automatic Hydraulic Presses for Elastomers & Polymeric components, liquid silicone rubber manufacturing and a fully equipped Laboratory with R&D Equipment, In-house Tooling & Mould making machinery, Laser Cut Machines, and Online Printing, as well as Marking systems on products.
In response to growing demands, we have significantly expanded our manufacturing capacity with the addition of a substantial facility. This facility serves as a comprehensive solution provider, enabling us to cater to the needs of clients worldwide. Our products are available globally, both directly and through our extensive distribution networks.
Do you hold certifications or have received awards that prove the quality standards of your products?
Committed to ethical business practices, our company upholds principles of Quick Development, Fastest Delivery, Ultimate Quality, and Competitive Rates.
Our dedication to quality is underscored by certifications such as ISO 9001:2015, ISO 14001:2015, ISO 45001:2018, ISO 27001:2013, and ISO 13485:2016, ensuring that our ISO Class VII Cleanroom facilities adhere to the highest standards.
In the domain of pharma and biopharma, we proudly hold certifications including BPOG extractable, FDA 21CFR, USP Class VI, EP 3.1.9, ADI Free, NSF-51 and other pertinent documents, reinforcing our commitment to serving customers worldwide.
Acknowledging our pursuit of excellence, we have received noteworthy recognitions, including the “Exceptional Partnership” accolade from Biocon Biologics at the Supplier Conclave 2023. Additionally, we were honoured with the “Best Bioprocessing Supplier in the Single-Use Consumables Category” award at the 2nd Edition of India Vaccine Leaders Conclave and the “Bioprocessing Supplier Award: Single Use Consumables” at the Asia Pacific Bioprocessing Excellence Awards 2023 hosted by IMAPAC.
Furthermore, our commitment was reaffirmed with the “Best Bioprocessing Supplier Award – Single-Use Systems” at the India Biologics and Vaccines Outstanding Contribution Awards 2022. These accolades stand as testaments to our unwavering commitment to excellence in the industry.
What are the emerging trends in your customers’ expectations and in the industry in general?
One of the major trends I have seen happening in the manufacturing industry this year is still manufacturing power by advancements in critical products for biopharmaceutical Industries.
The industry is in the midst of a fundamental transformation, as the scale of operations is growing. The year 2023 had bio-pharma companies oriented to staying agile and resilient in regards to disruption bred by the fluctuating market demands and diverse customer needs.
COVID-19 has put the global bio-pharmaceuticals industry into the spotlight with the world urgently working towards a breakthrough in the fight against the pandemic that results positively in the Production of vaccines and Advancements in technologies. The collaboration amongst the Innovation Discoveries of Life Sciences Companies is remarkable.
Furthermore, Developments and Improvements in Drug Research Boost in the Volume of Research in the Field. and More Value-Based Pricing of Biotech Products. Examining the evolving landscape of the Pharma & Biopharma industries, a significant trend is the substantial marketdemandforhigh-qualitysingle-usesystems coupled with rapid delivery. Recognizing this shift, we have proactively embraced this market trend by internalizing the production of all essential single-use products and associated components.
This includes developing in-house capabilities for tooling and design, ensuring that we meet our customers’ expectations for quality and swift delivery in this dynamic industry.
Website: www.amipolymer.com
Email: [email protected]
